In light of the covid-19 pandemic and the subsequent emergency use authorizations (euas) for sars-cov-2 diagnostic tests, the agency has requested heightened reporting beyond the reasonably suggests requirements of 803 to include allegations of false positive or false negative results independent of harm or malfunction or off-label use.Pursuant to the agency¿s instruction, we hereby submit this mdr.A customer alleged a discrepant result for influenza a with 1 patient sample while using the cobas sars-cov-2 & influenza a/b assay for use on the cobas 68/8800 systems.The alleged sample was initially tested on the cobas liat sars-cov-2 & influenza a/b assay twice generating a positive result for influenza a.The same sample was retested using the eplex respiratory panel generating a positive result for influenza a.The same sample was retested on the cobas 6800 generating a negative result for influenza a.The results were released.No harm was alleged.An investigation was conducted to evaluate the customer issue.Per fda¿s eua guidance, 1 mdr will be filed.
|